Intellia Q2 FY26 net loss widens to $106.63 million; revenue falls to $7.66 million
NTLA•Quarterly results
- Intellia posted a GAAP net loss of USD 106.63 million, widening from USD 101.26 million a year earlier; loss per share narrowed to USD 0.8 from USD 0.98.
- Collaboration revenue fell 46.24% to USD 7.66 million on lower Regeneron revenue; R&D expenses declined 14.85% to USD 82.6 million.
- G&A expenses climbed 38.99% to USD 37.82 million on commercial buildout costs, higher legal expenses, and stock-based compensation.
- Cash, cash equivalents and marketable securities totaled USD 628.35 million at quarter-end; operations expected to be funded at least into 2028.
Pipeline and regulatory update
- Intellia cited positive Phase 3 HAELO data for lonvo-z; expects FDA acceptance of its BLA in 2H 2026 and a U.S. launch in 1H 2027.
